Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study record history now shows a new revision entry v3.7.0, and the previously listed revision v3.6.6 has been removed.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedA new revision entry 'Revision: v3.6.6' appears in the study record history. This replaces the previous 'Revision: v3.6.5' and indicates an additional update to the record.SummaryDifference0.1%

- Check49 days agoChange DetectedA new revision entry v3.6.5 is added to the history, replacing v3.6.4, reflecting a software/UI update to the page.SummaryDifference0.1%

- Check63 days agoChange DetectedThe record history now includes a new revision entry (v3.6.4), indicating a page version update. This change affects only the page's metadata and does not modify the study data, conditions, or listings.SummaryDifference0.1%

- Check85 days agoChange DetectedA new revision entry v3.6.3 was added to the study record history, and the previous entry v3.6.2 was removed from the list.SummaryDifference0.1%

- Check92 days agoChange DetectedA new revision entry v3.6.2 was added to the study record history, and the previous revision v3.6.0 was removed.SummaryDifference0.1%

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.